In HER2-positive BC, antibodies against the extracellular domain of the HER2 receptor (trastuzumab) or inhibitors of tyrosine kinase activity of the receptor (lapatinib) improve disease survival [8,9] (Figure 1). The gene discussed is ERBB2; the disease is breast cancer.